Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815560 | 0.98 | KMT2A (0.43) | KMT2AMAP4K4ALDH1A1MEN1NPC1 | |
| SCHEMBL3225917 | 0.95 | KMT2A (0.43) | KMT2AMAP4K4ALDH1A1MEN1NPC1 | |
| SCHEMBL2816850 | 0.91 | KMT2A (0.45) | KMT2AOPRM1CYP3A4CASP1RECQL | |
| SCHEMBL11708337 | 0.82 | PDE4A (0.44) | KMT2AALDH1A1MEN1OPRM1CYP3A4 | |
| SCHEMBL11704967 | 0.79 | SLC6A3 (0.41) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL1019371 | 0.79 | SLC6A4 (0.53) | KMT2AMAP4K4ALDH1A1MEN1NPC1 | |
| SCHEMBL3171333 | 0.79 | WDR5 (0.47) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL16691395 | 0.79 | KMT2A (0.46) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL1020648 | 0.79 | SLC6A4 (0.49) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL2815381 | 0.78 | ALDH1A1 (0.55) | KMT2AMAP4K4ALDH1A1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | KMT2A 3959/4885MAP4K4 1677/4885ALDH1A1 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.